THE NLA is currently providing funding for cutting edge research into the development of a new therapeutic drug treatment for acute myeloid leukaemia.
Dr Graham Bailey, a research scientist at the University of Nottingham’s Medical School, is leading the research.
The work is focussed on a commonly occurring sub-type of acute myeloid leukaemia called NPM1-mutated AML. The aim of the research is to develop a novel gene therapy in which a drug selectively targets damaged copies of a gene which is believed to cause and maintain this type of leukaemia. Undamaged copies of the gene are not affected by the drug. This method of gene therapy should prevent the disease from progressing and eventually kill the leukaemia cells or make them more sensitive to conventional drugs. This is an entirely new method of treating the disease.
This research has the potential to create a radically new treatment which will benefit sufferers of acute myeloid leukaemia.